She has served as the Principal Investigator for numerous clinical trials evaluating the safety and immunogenicity novel live attenuated dengue vaccine candidates. These trials have led to the identification of a live attenuated tetravalent dengue vaccine that is currently being evaluated in in flavivirus-naïve and flavivirus-experienced volunteers in Brazil and Thailand and will soon begin Phase 3 efficacy trials in Brazil. She has, in collaboration with NIH scientists, developed a dengue human challenge model to down-select candidate dengue vaccines prior to the initiation of large-scale efficacy trials in endemic areas.